Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin T Jordan

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Journal of Neuro-Oncology|December 1, 2016
First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosisMojtaba Talaei-Khoei, Eric Riklin, Vanessa L Merker, et al.
Brain Communications|April 7, 2023
Vestibular dysfunction in neurofibromatosis type 2-related schwannomatosisAmsal S Madhani, Susan King, Jennifer Zhu, et al.
Neuro-Oncology|October 11, 2017
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendationsJohn C DeWitt, Justin T Jordan, Matthew P Frosch, et al.
Cancers|June 19, 2024
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related SchwannomatosisSimeng Lu, Zhenzhen Yin, Jie Chen, et al.
Journal of Neuro-Oncology|November 10, 2017
Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTTVanessa L Merker, Sarah McDannold, Eric Riklin, et al.
Neurology|June 25, 2025
Principles for Novel Neurologic Therapeutics: An AAN Position StatementLarry B Goldstein, Jonathan R Crowe, Anindita Deb, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 24, 2022
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosisJineta Banerjee, Jan M Friedman, Laura J Klesse, et al.
Orphanet Journal of Rare Diseases|February 1, 2021
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and researchHeather B Radtke, Bonita P Klein-Tasman, Vanessa L Merker, et al.
BMC Neurology|June 24, 2026
Characteristics, treatment patterns, healthcare resource use, and costs among adult patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas in the United StatesXiaoqin Yang, Mavis Obeng-Kusi, Theresa Dettling, et al.
Neurology|April 30, 2020
Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomicsYunpeng Liu, Justin T Jordan, Miriam A Bredella, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Journal of Neuro-Oncology|December 1, 2016
First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosisMojtaba Talaei-Khoei, Eric Riklin, Vanessa L Merker, et al.
Brain Communications|April 7, 2023
Vestibular dysfunction in neurofibromatosis type 2-related schwannomatosisAmsal S Madhani, Susan King, Jennifer Zhu, et al.
Neuro-Oncology|October 11, 2017
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendationsJohn C DeWitt, Justin T Jordan, Matthew P Frosch, et al.
Cancers|June 19, 2024
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related SchwannomatosisSimeng Lu, Zhenzhen Yin, Jie Chen, et al.
Journal of Neuro-Oncology|November 10, 2017
Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTTVanessa L Merker, Sarah McDannold, Eric Riklin, et al.
Neurology|June 25, 2025
Principles for Novel Neurologic Therapeutics: An AAN Position StatementLarry B Goldstein, Jonathan R Crowe, Anindita Deb, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 24, 2022
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosisJineta Banerjee, Jan M Friedman, Laura J Klesse, et al.
Orphanet Journal of Rare Diseases|February 1, 2021
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and researchHeather B Radtke, Bonita P Klein-Tasman, Vanessa L Merker, et al.
BMC Neurology|June 24, 2026
Characteristics, treatment patterns, healthcare resource use, and costs among adult patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas in the United StatesXiaoqin Yang, Mavis Obeng-Kusi, Theresa Dettling, et al.
Neurology|April 30, 2020
Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomicsYunpeng Liu, Justin T Jordan, Miriam A Bredella, et al.
Pageof 10